Dendritic cell–donor T lymphocyte interface (DC-T cell interface)

The dendritic cell–donor T lymphocyte interface is a specialized cellular junction, often referred to as the immunological synapse, where antigen-presenting dendritic cells interact with donor-derived T lymphocytes. This interface is the primary site for the initiation of the adaptive immune response, characterized by the presentation of host or donor antigens via Major Histocompatibility Complex (MHC) molecules to the T-cell receptor (TCR) (Dustin, 2014; Nature Reviews Immunology). In clinical settings such as hematopoietic stem cell transplantation, this interaction is central to the pathogenesis of graft-versus-host disease (GvHD), as donor T cells become activated against host tissues upon recognizing alloantigens at this interface (Koulnis et al., 2013; PMID: 23539238). Therapeutic intervention at this site typically involves blocking co-stimulatory pathways, such as the CD80/86-CD28 interaction, to prevent full T-cell activation and subsequent systemic inflammation. Drugs like abatacept (CTLA4-Ig) are specifically designed to modulate this interface by binding to CD80/86 on the dendritic cell, thereby inhibiting the necessary secondary signals for T-cell proliferation (FDA Label for Abatacept). Understanding the molecular dynamics of this interface is crucial for developing targeted immunosuppressive therapies that can prevent transplant rejection while minimizing broad immune suppression.

Other names

Immunological synapseDC-T cell interfaceAlloantigen presentation siteDendritic cell-T lymphocyte synapse

Disruption of co-stimulatory signals (e.g., CD80/86-CD28) and inhibition of MHC-TCR mediated activation at the cellular junction.